Skip to content

Evaluation of tau deposition using Florzolotau in young, healthy volunteers

Evaluation of tau deposition using Florzolotau in young, healthy volunteers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008809
Enrollment
30
Registered
2023-09-21
Start date
2024-09-02
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Gachon University Gil Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy subjects aged 20 or older but younger than 40 years old.

Exclusion criteria

Exclusion criteria: -Pregnant women (Excluded if there is even the slightest suspicion of pregnancy based on questionnaire responses, including the last menstrual date). -Currently breastfeeding women. -Patients with such poor overall health that it is difficult to perform the examination. -Individuals with conditions such as claustrophobia or other seizures. -Patients with clear diagnoses of other causes of dementia or major neurological conditions, including traumatic brain injury, Parkinson's disease, Huntington's disease, motor neuron diseases, multiple sclerosis, etc. -Patients diagnosed with psychiatric disorders such as schizophrenia. -Patients with brain tumors, hydrocephalus, encephalitis, metabolic encephalopathies. -Women who are pregnant or using intrauterine contraceptive devices. -Individuals with cardiac pacemakers or metallic substances implanted inside the body (However, exclusion does not apply if the implanted/transplanted material is titanium or a titanium alloy or if a specialist has confirmed that there are no issues with a 3T MRI scan). -Patients with metallic substances in the brain area, such as brain vascular clips, orthodontic devices, that can cause distortion of the MRI image. -Individuals who have been exposed to radiation exceeding an effective dose of 50msV (5rem) in the past year. -Individuals who have undergone PET scans, coronary angiograms, abdomen-pelvic CT scans, or similar procedures more than twice in the past year. -Individuals working in jobs with significant radiation exposure. -Other individuals who are deemed inappropriate for participation by the clinical investigator.

Design outcomes

Primary

MeasureTime frame
Formation of Florzolotau SUVR average maps for healthy subjects

Secondary

MeasureTime frame
Calculation of SUVR values in 6 regions associated with Braak stages

Countries

Korea, Republic of

Contacts

Public ContactYoung Noh

Gachon University Gil Medical Center

dementia9043@gmail.com+82-32-460-9043

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026